CAR Lentiviral Service
Viral vectors are efficient tools for modification of eukaryotic cells, and they are now used to introduce genes into mature T cells to generate immunity to cancer through the delivery of chimeric antigen receptors (CARs) or cloned T-cell receptors. Lentiviral vectors, derived from the human immunodeficiency virus, have been extensively investigated and optimized over the past two decades. CAR-T cell therapies engineered using lentiviral vectors have demonstrated noteworthy clinical success in patients with B-cell malignancies, leading to regulatory approval of the first genetically engineered cellular therapy using lentiviral vectors.